Sidoti Cuts Earnings Estimates for USANA Health Sciences

USANA Health Sciences, Inc. (NYSE:USNA) – Equities research analysts at Sidoti dropped their FY2026 earnings per share (EPS) estimates for shares of USANA Health Sciences in a research report issued on Wednesday, November 4th. Sidoti analyst A. Lebiedzinski now forecasts that the company will post earnings per share of $0.55 for the year, down from their prior estimate of $0.76. The consensus estimate for USANA Health Sciences’ current full-year earnings is $0.55 per share.

USANA Health Sciences (NYSE:USNA) last released its earnings results on Tuesday, November 3rd. The company reported ($0.11) EPS for the quarter, missing the consensus estimate of $0.11 by ($0.22). USANA Health Sciences had a negative net margin of 2.34% and a positive return on equity of 3.56%. The firm had revenue of $205.89 million during the quarter, compared to the consensus estimate of $217.42 million.

A number of other analysts have also commented on USNA. Wall Street Zen lowered shares of USANA Health Sciences from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of USANA Health Sciences in a research report on Monday, September 21st. Finally, Zacks Research raised shares of USANA Health Sciences from a “strong sell” rating to a “hold” rating in a research report on Monday, October 5th. One analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Reduce”.

USANA Health Sciences Stock Down 3.3%

Shares of USNA opened at $13.86 on Friday. USANA Health Sciences has a twelve month low of $12.57 and a twelve month high of $23.59. The stock has a market capitalization of $256.05 million, a P/E ratio of -12.05, a P/E/G ratio of 2.17 and a beta of 0.66. The company has a 50 day moving average of $14.61 and a 200-day moving average of $17.99.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. BlackRock Inc. bought a new position in USANA Health Sciences in the second quarter valued at approximately $33,182,000. Pzena Investment Management LLC acquired a new position in shares of USANA Health Sciences during the 2nd quarter worth approximately $25,739,000. Empowered Funds LLC bought a new stake in shares of USANA Health Sciences during the 2nd quarter worth approximately $1,500,000. Nantahala Capital Management LLC bought a new stake in shares of USANA Health Sciences during the 2nd quarter worth approximately $17,295,080. Finally, Bank of New York Mellon Corp bought a new stake in shares of USANA Health Sciences during the 2nd quarter worth approximately $1,105,000. 54.25% of the stock is owned by institutional investors and hedge funds.

More USANA Health Sciences News

Here are the key news stories impacting USANA Health Sciences this week:

• Positive Sentiment: Sidoti slightly raised its Q4 2026 EPS estimate to $0.12 from $0.11, a modest offset to its broader forecast reductions. USANA analyst estimates
• Negative Sentiment: USANA’s Q3 2026 results missed expectations: the company reported a loss of $0.11 per share versus consensus earnings of $0.11, while revenue of $205.9 million fell short of the $217.4 million estimate. Sales declined 4% year over year. USANA Q3 results and outlook
• Negative Sentiment: The company lowered its FY2026 outlook, now projecting net sales approaching $900 million and adjusted EBITDA of approximately $77 million. The reduced guidance suggests weaker near-term business performance. USANA updates its outlook
• Negative Sentiment: Sidoti lowered its FY2027 EPS forecast to $1.59 from $1.77 and cut estimates for Q1, Q2, and Q3 2027, indicating less confidence in earnings growth beyond 2026. USANA analyst estimates

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops and sells nutritional supplements, healthy foods and personal-care products through a direct-selling business model. Its product portfolio includes vitamins and mineral supplements, meal-replacement and snack products, sports nutrition offerings, and skincare products marketed under the USANA and related brands.

Founded in 1992 by microbiologist and immunologist Myron W. Wentz, the company is headquartered in Salt Lake City, Utah. USANA distributes its products through a network of independent associates and preferred customers rather than primarily through traditional retail channels.

The company serves customers in markets across the Americas, Asia-Pacific and Europe, with a significant presence in countries including the United States, Canada, Australia, New Zealand, China, Hong Kong, Japan, South Korea, the Philippines, Singapore, Malaysia and Thailand.